Third Harmonic Bio, Inc. (THRD) Dividend History

Third Harmonic Bio, Inc. is a clinical-stage biotechnology company focused on developing novel therapies targeting the immune system, particularly for acute and severe allergic and inflammatory conditions. The company's primary approach involves creating precision biologics aimed at modulating specific immune pathways to address unmet medical needs.

1700 Montgomery Street, San Francisco, CA, 94111
Phone: (209) 727-2457
Website: https://www.thirdharmonicbio.com

Dividend History

Third Harmonic Bio, Inc. currently does not pay dividends

Company News

Third Harmonic Bio Announces Plan of Liquidation and Dissolution

Third Harmonic Bio's board has approved a plan to liquidate and dissolve the company, seeking stockholder approval at the annual meeting in June 2025. The company plans to sell its assets, including the THB335 program, and distribute the remaining cash to shareholders.

GlobeNewswire Inc.
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape

Third Harmonic Bio is halting non-THB335 research, cutting 50% of its workforce, and reviewing strategic options as it prepares to advance THB335 into a Phase 2 trial for chronic spontaneous urticaria.

Benzinga
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November

Third Harmonic Bio, a clinical-stage biopharmaceutical company, announced that its CEO and CFO will participate in fireside chats at upcoming healthcare conferences. The company is focused on developing novel treatments for inflammatory diseases.

GlobeNewswire Inc.
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET.

GlobeNewswire Inc.
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector

Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.

Zacks Investment Research

Featured Companies: BIIB LLY

Dividend data last updated 06/07/2025 08:23:49 UTC